热门资讯> 正文
Immunic任命Jason Tardio为首席运营官兼总裁
2024-07-09 18:45
- Immunic (NASDAQ:IMUX) said it has appointed Jason Tardio to the newly created role of COO and President, effective July 12, 2024.
- Tardio most recently served as COO of Ovid Therapeutics since June 2021.
- The company also reported that Werner Gladdines, current Vice President, Program Management & Clinical Development Operations, has been promoted to Chief Development Officer.
More on Immunic
- Seeking Alpha’s Quant Rating on Immunic
- Historical earnings data for Immunic
- Financial information for Immunic
风险及免责提示:以上内容仅代表作者的个人立场和观点,不代表华盛的任何立场,华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前,应结合自身情况,考虑投资产品的风险。必要时,请咨询专业投资顾问的意见。华盛不提供任何投资建议,对此亦不做任何承诺和保证。